| Banff score . | cg . | ci . | ct . | cv . | ah . | ptc . | t . | i . | g . | v . |
|---|---|---|---|---|---|---|---|---|---|---|
| CNI group (n = 70) | ||||||||||
| 0 | 64 (91.4) | 2 (2.9) | 6 (8.6) | 0 (0) | 17 (24.3) | 68 (97.1) | 62 (88.6) | 63 (90) | 64 (91.4) | 70 (100) |
| 1 | 6 (8.6) | 26 (37.1) | 43 (61.4) | 0 (0) | 25 (35.7) | 2 (2.9) | 8 (11.4) | 7 (10) | 6 (8.6) | 0 (0) |
| 2 | 0 (0) | 27 (36.6) | 11 (15.7) | 45 (64.3) | 17 (24.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 3 | 0 (0) | 15 (21.4) | 10 (14.3) | 25 (35.7) | 11 (15.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Median (IQR) | 0 | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Belatacept group (n = 69) | ||||||||||
| 0 | 66 (95.6) | 2 (2.9) | 8 (11.6) | 0 (0) | 12 (17.4) | 64 (92.8) | 66 (95.7) | 63 (91.3) | 62 (89.9) | 69 (100) |
| 1 | 3 (4.4) | 23 (33.3) | 35 (50.7) | 0 (0) | 28 (40.6) | 5 (7.2) | 3 (4.3) | 6 (8.7) | 7 (10.1) | 0 (0) |
| 2 | 0 (0) | 33 (47.8) | 17 (24.6) | 45 (65.2) | 12 (17.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 3 | 0 (0) | 11 (16.0) | 9 (13.1) | 24 (34.8) | 17 (24.6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Median (IQR) | 0 (0–0) | 2 (1–2) | 1 (1–2) | 2 (2–3) | 1 (0.75–2) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| P-value* | .66 | .96 | .72 | .92 | .36 | .65 | .47 | .89 | .87 | .99 |
| Banff score . | cg . | ci . | ct . | cv . | ah . | ptc . | t . | i . | g . | v . |
|---|---|---|---|---|---|---|---|---|---|---|
| CNI group (n = 70) | ||||||||||
| 0 | 64 (91.4) | 2 (2.9) | 6 (8.6) | 0 (0) | 17 (24.3) | 68 (97.1) | 62 (88.6) | 63 (90) | 64 (91.4) | 70 (100) |
| 1 | 6 (8.6) | 26 (37.1) | 43 (61.4) | 0 (0) | 25 (35.7) | 2 (2.9) | 8 (11.4) | 7 (10) | 6 (8.6) | 0 (0) |
| 2 | 0 (0) | 27 (36.6) | 11 (15.7) | 45 (64.3) | 17 (24.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 3 | 0 (0) | 15 (21.4) | 10 (14.3) | 25 (35.7) | 11 (15.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Median (IQR) | 0 | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Belatacept group (n = 69) | ||||||||||
| 0 | 66 (95.6) | 2 (2.9) | 8 (11.6) | 0 (0) | 12 (17.4) | 64 (92.8) | 66 (95.7) | 63 (91.3) | 62 (89.9) | 69 (100) |
| 1 | 3 (4.4) | 23 (33.3) | 35 (50.7) | 0 (0) | 28 (40.6) | 5 (7.2) | 3 (4.3) | 6 (8.7) | 7 (10.1) | 0 (0) |
| 2 | 0 (0) | 33 (47.8) | 17 (24.6) | 45 (65.2) | 12 (17.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 3 | 0 (0) | 11 (16.0) | 9 (13.1) | 24 (34.8) | 17 (24.6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Median (IQR) | 0 (0–0) | 2 (1–2) | 1 (1–2) | 2 (2–3) | 1 (0.75–2) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| P-value* | .66 | .96 | .72 | .92 | .36 | .65 | .47 | .89 | .87 | .99 |
Banff scores: ah, arteriolar hyalinosis; cg, chronic glomerulopathy; ci, interstitial fibrosis; ct, tubular atrophy; cv, vascular fibrous intimal thickening; g, glomerulitis score; i, interstitial inflammation; ptc, peritubular capillaritis score; v, arteritis score.
| Banff score . | cg . | ci . | ct . | cv . | ah . | ptc . | t . | i . | g . | v . |
|---|---|---|---|---|---|---|---|---|---|---|
| CNI group (n = 70) | ||||||||||
| 0 | 64 (91.4) | 2 (2.9) | 6 (8.6) | 0 (0) | 17 (24.3) | 68 (97.1) | 62 (88.6) | 63 (90) | 64 (91.4) | 70 (100) |
| 1 | 6 (8.6) | 26 (37.1) | 43 (61.4) | 0 (0) | 25 (35.7) | 2 (2.9) | 8 (11.4) | 7 (10) | 6 (8.6) | 0 (0) |
| 2 | 0 (0) | 27 (36.6) | 11 (15.7) | 45 (64.3) | 17 (24.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 3 | 0 (0) | 15 (21.4) | 10 (14.3) | 25 (35.7) | 11 (15.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Median (IQR) | 0 | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Belatacept group (n = 69) | ||||||||||
| 0 | 66 (95.6) | 2 (2.9) | 8 (11.6) | 0 (0) | 12 (17.4) | 64 (92.8) | 66 (95.7) | 63 (91.3) | 62 (89.9) | 69 (100) |
| 1 | 3 (4.4) | 23 (33.3) | 35 (50.7) | 0 (0) | 28 (40.6) | 5 (7.2) | 3 (4.3) | 6 (8.7) | 7 (10.1) | 0 (0) |
| 2 | 0 (0) | 33 (47.8) | 17 (24.6) | 45 (65.2) | 12 (17.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 3 | 0 (0) | 11 (16.0) | 9 (13.1) | 24 (34.8) | 17 (24.6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Median (IQR) | 0 (0–0) | 2 (1–2) | 1 (1–2) | 2 (2–3) | 1 (0.75–2) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| P-value* | .66 | .96 | .72 | .92 | .36 | .65 | .47 | .89 | .87 | .99 |
| Banff score . | cg . | ci . | ct . | cv . | ah . | ptc . | t . | i . | g . | v . |
|---|---|---|---|---|---|---|---|---|---|---|
| CNI group (n = 70) | ||||||||||
| 0 | 64 (91.4) | 2 (2.9) | 6 (8.6) | 0 (0) | 17 (24.3) | 68 (97.1) | 62 (88.6) | 63 (90) | 64 (91.4) | 70 (100) |
| 1 | 6 (8.6) | 26 (37.1) | 43 (61.4) | 0 (0) | 25 (35.7) | 2 (2.9) | 8 (11.4) | 7 (10) | 6 (8.6) | 0 (0) |
| 2 | 0 (0) | 27 (36.6) | 11 (15.7) | 45 (64.3) | 17 (24.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 3 | 0 (0) | 15 (21.4) | 10 (14.3) | 25 (35.7) | 11 (15.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Median (IQR) | 0 | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Belatacept group (n = 69) | ||||||||||
| 0 | 66 (95.6) | 2 (2.9) | 8 (11.6) | 0 (0) | 12 (17.4) | 64 (92.8) | 66 (95.7) | 63 (91.3) | 62 (89.9) | 69 (100) |
| 1 | 3 (4.4) | 23 (33.3) | 35 (50.7) | 0 (0) | 28 (40.6) | 5 (7.2) | 3 (4.3) | 6 (8.7) | 7 (10.1) | 0 (0) |
| 2 | 0 (0) | 33 (47.8) | 17 (24.6) | 45 (65.2) | 12 (17.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 3 | 0 (0) | 11 (16.0) | 9 (13.1) | 24 (34.8) | 17 (24.6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Median (IQR) | 0 (0–0) | 2 (1–2) | 1 (1–2) | 2 (2–3) | 1 (0.75–2) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
| P-value* | .66 | .96 | .72 | .92 | .36 | .65 | .47 | .89 | .87 | .99 |
Banff scores: ah, arteriolar hyalinosis; cg, chronic glomerulopathy; ci, interstitial fibrosis; ct, tubular atrophy; cv, vascular fibrous intimal thickening; g, glomerulitis score; i, interstitial inflammation; ptc, peritubular capillaritis score; v, arteritis score.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
